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Background: The decreased ability to carry out vertical saccades is a key symptom of
Progressive Supranuclear Palsy (PSP). Objective measurement devices can help to reliably
detect subtle eye movement disturbances to improve sensitivity and specificity of the
clinical diagnosis. The present study aims at transferring findings from restricted stationary
video-oculography (VOG) to a wearable head-mounted device, which can be readily
applied in clinical practice. Methods: We investigated the eye movements in 10 possible
or probable PSP patients, 11 Parkinson’s disease (PD) patients, and 10 age-matched
healthy controls (HCs) using a mobile, gaze-driven video camera setup (EyeSeeCam).
Ocular movements were analyzed during a standardized fixation protocol and in an
unrestricted real-life scenario while walking along a corridor. Results: The EyeSeeCam
detected prominent impairment of both saccade velocity and amplitude in PSP patients,
differentiating them from PD and HCs. Differences were particularly evident for saccades
in the vertical plane, and stronger for saccades than for other eye movements. Differences
were more pronounced during the standardized protocol than in the real-life scenario.
Conclusions: Combined analysis of saccade velocity and saccade amplitude during the
fixation protocol with the EyeSeeCam provides a simple, rapid (<20 s), and reliable tool
to differentiate clinically established PSP patients from PD and HCs. As such, our findings
prepare the ground for using wearable eye-tracking in patients with uncertain diagnoses.
Keywords: progressive supranuclear palsy, mobile eye-tracking, eye movements, Parkinson’s disease, video-
oculography
INTRODUCTION
Eye movement abnormalities are an essential clinical feature of
Progressive Supranuclear Palsy (PSP). Vertical supranuclear gaze
palsy or decreased velocities of vertical saccades are a key to
the clinical diagnosis of PSP (Litvan et al., 1996). Besides their
role as diagnostic signs, eye movement abnormalities disable PSP
patients in their daily routine.
Stationary video-oculography (VOG) during head-fixed view-
ing shows that virtually all forms of eye movements are affected
in PSP, with saccadic eye movements being most prominently
impaired. Particularly vertical saccades show reduced amplitude
and peak velocity when compared to Parkinson’s disease (PD)
patients and healthy controls (HCs) (Pinkhardt et al., 2008; Chen
et al., 2010; Pinkhardt and Kassubek, 2011). Vergence movements
and the associated modulation of the linear vestibuloocular reflex
are also considerably affected (Chen et al., 2010). The presence of
horizontal square wave jerks during attempted fixation of station-
ary targets is characteristic of PSP (Chen et al., 2010; Otero-Millan
et al., 2011). Among these deficits, saccadic peak velocity in the
vertical plane shows the sharpest contrast between PSP and PD
(Pinkhardt and Kassubek, 2011).
These PSP-specific eye movement abnormalities make clini-
cal investigation of eye movements in patients with Parkinsonian
syndromes of great value for differential diagnosis. Correct diag-
nosis of PSP remains challenging, especially in its early stages
(Burn and Lees, 2002). Eye movement abnormalities are not
always easy to detect clinically. Particularly, slowing of saccades is
a characteristic symptom that can be missed by less experienced
neurologists.
Objective measurement devices aid detection of subtle eye
movement disturbances. Stationary VOG setups typically require
careful calibration, need patient collaboration, and are thus
largely impractical for clinical routine. Head-fixed viewing
lacks vestibular and other cross-modal information, leaving the
relevance of observed eye movement impairment for real-life
behavior open. As a first step toward the development of an
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objective, easy-to-use method for eye movement-based diagnosis,
we here tested if recording eye movements with the versatile,
head-mounted EyeSeeCam (Brandt et al., 2006; Schneider et al.,
2006, 2009) in a brief and simple fixation protocol can dif-
ferentiate between patients with clinically established PSP as
compared to established PD and HCs, and measured gaze in
these groups during free behavior. We aimed at establishing
the EyeSeeCam’s usage in PD and PSP cases and validating
its discriminative power between these groups. The parameters
established in the present study in clinically established patients
shall pave the way for prospective studies with uncertain diag-
noses.
MATERIALS AND METHODS
PARTICIPANTS
Patients examined in the Department of Neurology of the
University of Marburg qualified for participation in the study, if
they had clinically possible or probable PSP (Litvan et al., 1996)
and were not more advanced than Hoehn and Yahr stage IV
(Golbe and Ohman-Strickland, 2007). As defined by the NINDS-
SPSP criteria (Litvan et al., 1996), all patients had supranuclear
gaze palsy or slowing of vertical saccades at the time of exam-
ination, as evidenced by an examiner specialized in the clinical
evaluation of ocular movements.
As controls, we included patients with clinically probable PD
(Gibb and Lees, 1988) and HCs. HCs were free of neurologic,
systemic, or psychiatric diseases, including alcohol or substance
abuse, as verified by detailed evaluation of their medical histories
and a comprehensive physical examination.
Further exclusion criteria were other neurological disor-
ders, dementia (mini mental status examination <24), presently
active psychiatric disorder (e.g., depression or psychosis), struc-
tural brain lesion (e.g., brain surgery, stroke with persistent
neurological deficit), cataract, or other neuro-ophthalmological
disorders leading to functionally relevant impairment. Since
glasses cannot be worn with the EyeSeeCam, people requir-
ing visual correction by glasses stronger than ±2 dpt were also
excluded.
Before inclusion into the study, participants gave their
informed written consent. All procedures conformed to the
Declaration of Helsinki and were approved by the local
ethics committee (Ethikkommission FB20, Philipps-Universität
Marburg).
EYE AND HEAD MOVEMENT RECORDINGS
We used a mobile VOG setup (EyeSeeCam) to record the partic-
ipants’ eye and head movements. Participants accustomed them-
selves to wearing the device, while the experimental procedure
was explained.
The head-mounted device consists of a head-fixed camera to
record the perspective of the head, two high-speed cameras track-
ing eye-in-head movements, and a camera, which is automatically
aligned with the observer’s direction of gaze. Gaze- and head-
centered videos are recorded at 25Hz (Figure 1A; Movie 1 in
supplementary material); eye movements at 300Hz.
According to manufacturer’s specifications, the spatial resolu-
tion of the eye-tracking device is given to 0.02◦ and the precision
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FIGURE 1 | (A) Example frame at 43.81 s in the real-life measurement,
while a PD patient was looking at the clock; left: gaze camera, right: head
camera. The movie of this scene including velocity histograms is shown as
supplemental online Movie 1. (B) Eye-traces of the scene. Upper panel:
Horizontal eye position, indicating the horizontal amplitude of saccades;
starting and end points of saccades are marked by green and cyan dashes
lines, respectively; durations of saccades are highlighted by a white
background. Middle panel: Vertical eye position, indicating the vertical
amplitude of the same saccades. Lower panel: Absolute eye velocity,
arrows mark saccade peak velocities, used for analysis.
(relative error) on the order of 0.1◦ (“maximal resolution error,”
Schneider et al., 2009). The accuracy (absolute error) of the
device under ideal conditions is about 0.5◦ according to specifi-
cations, and can substantially worsen if the goggles move relative
to the head during prolonged measurements without recalibra-
tion. Hence, all analysis reported here only use relative measures,
which are unaffected by these drifts, such as velocities and saccade
amplitudes.
Being not concerned with absolute gaze orientation (i.e., with
high accuracy) comes at the advantage that the device may be
operated using an internal (“default”) model of ocular geome-
try for all participants. In this mode of operation, the mapping
from eye measurements on gaze direction does not require a
subject-specific calibration, which is in particular beneficial in
patients with limited ocular motor control or limited compli-
ance with instructions. Although this sacrifices some precision
(depending on the actual head shape compared to the default
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model), no systematic effect on the measures analyzed here
can be expected. For the “fixation protocol” (see below), the
default model was used in all participants; for the “real-life mea-
surements” (see below), in those participants, in whom it was
possible, the subject-specific model obtained from the fixation
protocol was used; for the remainder the default model was also
used in real-life measurements. Since the subject-specific adap-
tation of the model represents a calibration procedure for abso-
lute position, for the real-life measurement, these participants
will be referred to as successfully and unsuccessfully calibrated,
respectively.
When extracting headmovements from the head fixed camera,
for the analysis conducted here, the spatial resolution is limited
by the pixel width of about 0.3◦, even though sub-pixel analysis
would be possible in principle. When analysis is based on sub-
sequent frames, this limits the resolution for head movements
to about 7.5◦/s. While integration over multiple frames would
be possible to lower this number, this would come at the cost
of lower temporal resolution and thus possibly lumping distinct
head movements into one.
Fixation protocol
To test the utility of the EyeSeeCam as diagnostic tool, we
employed a “fixation protocol.” In addition to being the first
experimental part, this protocol also served to refine the
EyeSeeCam’s calibration for the subsequent real-life experiments
by adapting the system’s internal eye model to the individual.
During the fixation protocol, the participants’ heads were unre-
strained, but they were asked to avoid head movements as far as
possible. They were instructed to move their eyes to look suc-
cessively at 5 laser dots projected onto a wall straight ahead, a
central dot and four at 8.5◦ in the cardinal directions. An exper-
imenter pointed with a finger at the dot the participant should
look at. To give the participant the possibility to self-pace their
fixations, presentation of the dots in time was to some degree flex-
ible and not exactly clocked. However, the participant had to look
at each dot for 2 s at least once in a time span of approximately
20 s. While this procedure is far less constrained and standardized
than usual laboratory measurements, it is still more controlled
than the real-life conditions of the present study. This flexible
and efficient procedure makes the participation of very severely
affected patients possible, presenting a clear advantage over more
constrained settings.
Real-life behavior
Formeasuring a large range of gaze behaviors as occurring in real-
life situations, we asked participants to perform a series of tasks,
while spontaneous eye and head movements were recorded. First,
free-exploration behavior was assessed by asking participants to
walk along a 50m corridor. Right before the participant turned
around at the end of the corridor, an experimenter laid two paper
spots on the floor to assess tracking behavior. Participants were
asked to track the dots with their eyes, while walking back toward
them. Finally, participants took the elevator and descended one-
level to test a situation without active movement in a confined
visual environment with subtle vestibular input. Those two PSP
and PD patients who were wheelchair-dependent were wheeled
throughout the whole procedure by an experimenter instead of
actively walking.
The objective of the real-life measurement was to provide
a naturalistic set of behaviors, while differences between real-
life conditions were not at the focus of the current study.
Consequently, all data of real-life measurement were pooled per
participant. The real-life measurement lasted less than 10min per
participant.
DATA ANALYSIS AND STATISTICAL EVALUATION
Eye movements
Raw eye-position data were processed offline using MATLAB
(Matlab 7.10, The MathWorks, Natick, MA), which was also used
for statistical analysis. We calculated eye velocity by differenti-
ation of the horizontal and vertical eye position (Figure 1B).
Absolute speed was then calculated as the square root of the
sum of the squared horizontal and squared vertical velocity
componentss.
All phases faster than 60◦/s and lasting longer than 10ms are
referred to as “saccades,” irrespective of whether they were actual
saccades or fast phases of reflexive movements (Figure 1B). This
threshold is higher than those typically used in laboratory set-
tings, as signals obtained during real-life measurements contain
rich eye movement dynamics and are typically noisier than under
constrained settings. The conservative choice is, however, consis-
tent with previous research on eyemovements in PSP patients: for
example, judging from the figures in Pinkhardt et al. (2008), their
patients had their 5% percentile of peak saccade velocities around
or above 60◦/s, meaning that we can still expect to include about
95% of actual saccades with our comparably conservative crite-
rion. Since this criterion could also be employed in practice, it
will not affect any conclusion on the discriminability of patient
groups. Nonetheless, for the general questions pertaining to eye
movement disturbances in PSP and PD, the fact that any thresh-
old must remain arbitrary motivates to add an analysis that does
not classify eye movements in saccade/non-saccade, but uses the
unclassified (i.e., raw) eye movement data (see below and section
“Unclassified Eye Movements”).
Parameters to describe saccades were their direction, peak
velocity, amplitude, and duration (Figure 1B). Since peak
velocity, saccade amplitude, and duration are typically not inde-
pendent, the functional relationship of amplitude and peak veloc-
ity and of amplitude and saccade duration, the so-called main
sequence (Bahill et al., 1975), was also considered for real-life
data: we fitted the relation with a power function of the form
velocity = a × amplitudeb or duration= a × amplitudeb, respec-
tively (cf. Garbutt et al., 2003), and considered only the fit param-
eters a and b further. Since reliable fits of main sequences require
substantial amounts of data, this analysis was only performed for
the real-life measurements.
To test whether there is an abundance of one saccade direc-
tion in a group, we coarsely classified saccades into equally
spaced 45◦ wedges: horizontal (±22.5◦ from the horizontal),
vertical (±22.5◦ from the vertical), and oblique (the remaining
4 × 45◦ = 180◦).
For analysis of raw (“unclassified”) eye data (i.e., all
data irrespective of whether defined as saccade or not),
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two-dimensional histograms were used. Each bin of the his-
tograms used for analysis corresponds to a velocity interval of
15◦/s in each direction (horizontal and vertical); the central bin
ranges from −7.5◦/s to +7.5◦/s in each direction. The number of
samples in each bin is color-coded.
Head movements
Head movements were computed from the video of the head-
fixed camera at 25Hz. To obtain head position, the same station-
ary point of the environment was marked in each video-frame.
From this point’s position in the camera’s field of view relative
head orientation in the world was computed. Head velocity was
obtained by differentiation of this signal, and was thus inde-
pendent of this choice of origin. All quantitative analysis was
therefore based on velocities. Unlike for eye movements and due
to the low spatial and temporal resolution (section “Eye and Head
Movement Recordings” top), we could not classify head move-
ments in distinct classes (e.g., fast/slow) with the data at hand.
Therefore, all analysis was based on overall velocity distributions
for each individual.
Statistical analysis
Data are presented as mean ± standard deviation. Statistical
evaluation used non-parametric tests for raw eye data, such
as amplitude and peak velocity of each saccade (Kruskal–
Wallis when three groups were compared and Mann–Whitney-
U-Test for two groups). To compare these parameters in an
exploratory manner across participants, the individual distribu-
tions are described by their medians as robust measure (since
the distributions are either leptokurtic or prone to outliers).
Since these medians can be assumed to follow a normal dis-
tribution across participants, the group effects were analyzed
by parametric tests; that is, ANOVAs for three group com-
parisons and two-tailed t-tests for two-group comparisons and
post-hoc tests.
Signal-detection-theory measures
For assessing the performance of the classifiers between PSP and
PD patients, we performed signal-detection analysis by comput-
ing the Receiver-Operating-Characteristic (ROC). The ROC is
quantified by its area under the curve (AUC), the cut-off point for
maximal specificity and sensitivity, and the corresponding values
of specificity and sensitivity. Values are reported such that all val-
ues of patients classified as PSP patients are strictly smaller than
this cut-off value.
RESULTS
PARTICIPANT CHARACTERISTICS
We investigated 10 PSP patients (6 probable, 4 possible), 11 PD
patients and 10 HCs (Table 1). All patients were under treatment
in the University Hospital in Marburg. There were no significant
differences regarding age, disease duration, and gender between
the groups. For all patients Hoehn and Yahr stage was assessed in
off-state and, as expected, the stages differed significantly between
PSP and PD patients (Table 1).
Eye velocities and relative eye positions (e.g., saccade
amplitudes) require only minimal subject–specific adjustment
Table 1 | Clinical characteristics of the participants in this study:
overview.
PSP PD HC
N 10 11 10
Age (years) 65.9 ± 4.6 65.5 ± 12.7 68.3 ± 9.1
Gender (F/M) 3/7 3/8 6/4
DD (years) 3.9 ± 2.7 6.2 ± 4.7 –
H&Y 3.9 ± 0.4 2.5 ± 0.4
Wheelchair 2/10 2/11 0/10
Real-life
measurement time
304.3 ± 114.4 s 242.2 ± 78.5 s 202.8 ± 35.3 s
Details
Patient
ID/gender/age
[years]
Onset Exam. date H&Y Medication
PSP01/F/67 2004 08/2010 4 Levodopa
PSP02/M/70 2008 08/2010 3 Amantadine
PSP03/F/63 2007 08/2010 4 Levodopa,
Amantadine
PSP04/M/70 2007 08/2010 4 Levodopa,
Amantadine,
Piribedil
PSP05/F/65 2007 08/2010 3 Amantadine,
Rotigotine
PSP06/M/67 2000 08/2010 4 Levodopa
PSP07/M/62 2008 02/2011 4 Levodopa
PSP08/M/74 2005 05/2011 4 Levodopa,
Amantadine
PSP09/M/59 2010 10/2011 3 Levodopa
PSP10/M/62 2009 11/2011 3 Levodopa
PD01/M/61 2007 09/2010 2 Rotigotine
PD02/M/75 1995 09/2010 3 Levodopa
PD03/M/75 2007 02/2011 1 Ropinirole
PD04/M/64 2000 07/2011 3 Levodopa,
Amantadine,
Pramipexole,
Rasagiline
PD05/M/67 2007 07/2011 1 Levodopa,
Ropinirole,
Rasagiline
PD06/M/51 2010 09/2011 2 Levodopa,
Rasagiline
PD07/F/62 2007 10/2011 3 Levodopa,
Rasagiline,
Piribedil
PD08/M/38 2010 10/2011 2 Pramipexole
PD09/M/78 2007 12/2011 3 Levodopa
PD10/F/82 2001 12/2011 3 Levodopa,
Amantadine,
Ropinirole
PD11/F/68 2000 12/2011 3 Levodopa,
Amantadine,
Pramipexole
HC01/F/58 08/2010
HC02/M/71 08/2010
(Continued)
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Table 1 | Continued
Patient
ID/gender/age
[years]
Onset Exam. date H&Y Medication
HC03/F/53 02/2011
HC04/F/63 02/2011
HC05/M/73 03/2011
HC06/F/64 03/2011
HC07/F/69 03/2011
HC08/F/74 09/2011
HC09/M/85 12/2011
HC10/M/73 12/2011
PSP, progressive supranuclear palsy; PD, Parkinson’s disease; HC, healthy
controls; DD, disease duration; H&Y, Hoehn and Yahr Stage. H&Y stage is
significantly different between PD and PSP [t(19) = 4.12, p < 0.001]; real-life
measurement duration differs significantly between PSP and HC (p = 0.02
post-hoc test); all other comparisons do not show a significant difference
(p > 0.05).
and could thus be measured accurately in all participants.
However, individual-specific calibration of absolute eye-position
failed in eight PSP and two PD patients as a conse-
quence of their inability to steadily fixate instructed tar-
gets over a 2-s integration window. Interestingly, this inabil-
ity did not primarily result from square-wave jerks, which
were robustly observed only in 1 out of the 10 PSP patients
under our experimental conditions. As a consequence of the
calibration failures for absolute position, all quantitative anal-
ysis hereafter is based on relative eye-position and veloci-
ties only.
SACCADES
Fixation protocol
All participants performed a standard fixation protocol, as
described in the “Materials and Methods” section, which was
also used for individual calibration refinement. Irrespective of
whether this absolute-position calibration was successful or not,
these measurements provided a sufficient number of visually-
guided saccades to analyze differences between PSP patients and
PD patients or HCs (Figure 2).
Averaged median saccadic peak velocity was 135.1 ± 43.8◦/s
for PSP, 220.1 ± 31.5◦/s for PD patients and 233.0 ± 44.4◦/s
for HCs. A One-Way ANOVA revealed a significant main
effect [F(2, 28) = 17.81, p < 0.001, Figure 2B] and post-hoc t-
tests showed that PSP patients generated saccades with signif-
icantly slower median peak velocity than PD patients [t(19) =
5.14, p < 0.001] and HCs [t(18) = 4.96, p < 0.001]. There were
also significant differences in the vertical components of sac-
cade peak velocity. Averaged vertical saccade peak velocity was
54.9 ± 28.0◦/s for PSP patients, 158.5 ± 47.9◦/s for PD patients
and 151.1 ± 60.3◦/s for HCs [F(2, 28) = 14.53, p < 0.001; PSP-
PD: t(19) = 5.83, p < 0.001; PSP-HC: t(18) = 4.51, p < 0.001,
Figure 2C].
Saccade amplitudes also differed significantly between groups
[F(2, 28) = 18.26, p < 0.001, PSP-PD: t(19) = 4.26, p < 0.001,
PSP-HC: t(18) = 6.60, p < 0.001, Figure 2B]. Averaged median
amplitudes were 1.88 ± 0.72◦ for PSP patients, 4.16 ± 1.53◦
for PD patients and 5.42 ± 1.53◦ for HCs. Vertical saccade
amplitude was 0.52 ± 0.37◦ for PSP patients, 2.89 ± 1.62◦ for
PD patients and 3.03 ± 2.16◦ for HCs and thus also differed
significantly [F(2, 28) = 7.76, p = 0.002; PSP-PD: t(19) = 4.37,
p < 0.001; PSP-HC: t(18) = 3.57, p = 0.002, Figure 2C].
We did not find significant main effects for the horizontal
components of peak velocity [F(2, 28) = 2.12, p = 0.14, ANOVA;
Figure 2D] and amplitude [F(2, 28) = 1.69, p = 0.20, Figure 2D].
The ROC comparing saccade peak velocity of PSP and PD
patients showed an AUC of 0.95. Specificity was 11/11 and sen-
sitivity was 9/10 for a cut-off value of 189.8◦/s (i.e., all patients
having slower peak velocities than this value were classified as
PSP) patients. For the comparison of vertical saccade peak veloc-
ities, the AUC was 1 and for the cut-off value 111.7◦/s, specificity
was 11/11 and sensitivity was 10/10. The AUC for the compar-
ison of saccade amplitude was 0.97 with a specificity of 11/11
and a sensitivity of 9/10 for a cut-off value of 2.79◦. For the ver-
tical component, AUC was 0.99 and the ROC analysis showed
a specificity of 10/11 and a sensitivity of 10/10 for the cut-off
value 1.68◦.
For completeness, we also analyzed saccade duration in all
groups. We found a significant main effect between groups [PSP:
19.6 ± 7.2ms, PD: 26.2 ± 6.3ms, HC: 32.7 ± 6.5ms, F(2, 28) =
9.6, p < 0.001, see Figures 2E,F]. Post-hoc t-test revealed signif-
icant differences between all groups [PSP-PD: t(19) = 2.25, p =
0.037; PSP-HC: t(18) = 4.27, p < 0.001; PD-HC: t(19) = 2.30,
p = 0.033]. Sensitivity was 7/10 and specificity was 9/11 for the
cut-off value 21.6ms, the AUC was 0.77. These values are much
lower than for amplitude and peak velocity and thus less informa-
tive where differential diagnosis is concerned. Hence, we hereafter
focus most analysis on peak velocity and amplitude.
Real-life
Since the eye movement impairment in PSP was evident dur-
ing the fixation protocol, we next analyzed their relevance for
real-life situations. Hence, we measured the spontaneous ocu-
lar motor behavior in a real-life, minimally restrained scenario,
comprising self-paced walking in a corridor, tracking of a sta-
tionary target, and taking an elevator. Self-paced walking implies
speed differences between participants. ANOVA revealed a signif-
icant main effect for differences in real-life measurement duration
[F(2, 28) = 3.85, p = 0.03, Table 1]; the difference was not signifi-
cant between PSP and PD patients, but for HCs the measurement
lasted significantly shorter than for PSP patients [t(18) = 2.68,
p = 0.02]. Aggregating over the whole real-life measurement, we
assessed the same parameters as during the fixation protocol
(Figure 3).
All groups had the same fraction of vertical [PSP: 24.1% ±
15.4%, PD: 28.9% ± 10.4%, HC: 31.7% ± 7.1%, F(2, 28) =
1.14, p = 0.33], horizontal [PSP: 21.7% ± 9.0%, PD: 18.5% ±
8.1%, HC: 18.3% ± 5.9%, F(2, 28) = 0.64, p = 0.53] and oblique
[PSP: 54.3% ± 10.1%, PD: 52.6% ± 6.1%, HC: 50.0% ± 3.7%,
F(2, 28) = 0.92, p = 0.41] saccades.
The medians of saccade peak velocity differed significantly
between the groups [F(2, 28) = 5.47, p = 0.01, Figure 3B]. PSP
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FIGURE 2 | (A) Medians of saccade peak velocity and amplitude for each
participant during the fixation protocol. (B) Mean over participants of
median amplitude (left panel) and median peak velocity (right panel) for
each group. (C) Vertical component and (D) horizontal component of the
data of panel (B); (E) Medians of saccade duration and amplitude for each
participant during fixation protocol; note that the duration is discretized due
to sampling frequency (F). Mean over participants of median duration.
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
patients’ averaged median saccade peak velocity was 131.1 ±
29.0◦/s and thus slower than those of PD patients [163.1 ±
25.8◦/s; t(19) = 2.68, p = 0.002] and HCs [160.2 ± 15.4◦/s;
t(18) = 2.80, p = 0.01]. The vertical component of saccade peak
velocity (PSP: 71.9 ± 15.5◦/s, PD: 89.6 ± 11.5◦/s, HC: 89.5 ±
9.6◦/s) also differed significantly [F(2, 28) = 6.88, p = 0.004, PSP-
PD: t(19) = 3.00, p = 0.007; PSP-HC: t(18) = 3.05, p = 0.007,
Figure 3C], whereas there was no significant difference between
means of the horizontal component of peak velocity [F(2, 28) =
1.66, p = 0.21, Figure 3D] between groups.
ANOVA did not reveal a significant main effect for saccade
amplitude [F(2, 28) = 2.55, p = 0.10, Figure 3B], but the vertical
component of saccade amplitude differed significantly [F(2, 28) =
3.46, p = 0.045, Figure 3C]; post-hoc t-tests revealed that PSP
patients’ vertical component of saccade amplitude was signif-
icantly shorter (0.79 ± 0.36◦) than PD patients’ [1.12 ± 0.33◦;
t(19) = 2.12, p = 0.047] and HCs’ [1.06 ± 0.13◦; t(18) = 2.16,
p = 0.04]. There was no significant difference between medi-
ans of the horizontal components of amplitudes [F(2, 28) = 0.25,
p = 0.78, Figure 3D].
The AUC was 0.84 for peak velocity with a sensitivity of 8/10
and a specificity of 9/11 for the cut-off value 139.9◦/s. For ver-
tical peak velocity, the AUC was 0.82 and for a cut-off value of
83.2◦/s sensitivity was 7/10 and specificity was 8/11. For analy-
sis of saccade amplitudes, the AUC was 0.80 with a sensitivity
of 8/10 and a specificity of 8/11 for a cut-off value of 1.85◦.
The AUC for comparison of vertical components was 0.75 with
a sensitivity of 6/10 and a specificity of 11/11 for the cut-off
value 0.69◦.
Differences in medians of saccade duration were not sig-
nificantly different between groups [PSP: 25.5 ± 3.7ms, PD:
27.6 ± 4.0ms, HC: 25.6 ± 2.3ms, F(2, 28) = 1.31, p = 0.29; see
Figures 3E,F].
Correlation between fixation protocol and real-life
Median of peak velocity and its vertical component in the fix-
ation protocol and during real-life measurement correlated sig-
nificantly (N = 31, r = 0.39, p = 0.03; vertical: r = 0.50, p =
0.004). Thus, the data collected during the fixation protocol not
only differentiated between PSP and PD patients, but also in part
predicted real-life performance.
Main-sequence analysis
Peak velocity and duration were plotted as a function of ampli-
tude for each saccade of every participant. We fitted this main
sequence with a power function (Figure 4A) and compared the fit
parameters between groups. There were no significant differences
between groups with respect to the value of fit parameters a
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FIGURE 3 | Continued
FIGURE 3 | (A) Medians of saccade peak velocity and amplitude for each
participant during real-life measurement. (B) Mean over participants of
median amplitude (left panel) and median peak velocity (right panel) for
each group. (C) Vertical component and (D) horizontal component of the
data of panel (B). (E) Medians of saccade duration and amplitude for each
participant during real-life measurement; note that the duration is
discretized due to sampling frequency (F). Mean over participants of
median duration. ∗p < 0.05; ∗∗p < 0.01.
[F(2, 28) = 1.69, p = 0.20, Figure 4B] and b [F(2, 28) = 1.38, p =
0.27, Figure 4C]. There were also no differences between groups
in the vertical component of saccades [value of a: F(2, 28) =
2.54, p = 0.097, Figure 4D; value of b: F(2, 28) = 1.08, p = 0.35,
Figure 4E] and in the value of the fit parameter a of the func-
tional relationship between duration and amplitude [F(2, 28) =
0.02, p = 0.98, Figure 4F]. There was a significant main effect for
the values of b in that case [F(2, 28) = 4.11, p = 0.027, Figure 4G]
but post-hoc t-tests did not reveal significant differences between
PSP and PD patients [t(19) = 1.77, p = 0.09] or PD patients and
HCs [t(19) = 1.24, p = 0.23]. The only significant difference was
found between PSP patients and HCs [t(18) = 2.43, p = 0.026].
UNCLASSIFIED EYE MOVEMENTS
Under real-life conditions, fast eye movement phases (saccades),
as analyzed above, accounted for only a small amount of the
entire measurement time (PSP: 7.6 ± 3.8%, PD: 11.7% ± 7.9%,
HC: 10.4% ± 2.8%). To compare saccade-based analysis to all eye
movements, we generated 2-dimensional velocity histograms for
saccades only (Figure 5A) and for all eye movements (“unclassi-
fied movements,” Figure 5B) during the entire real-life measuring
time. The histograms show pooled data from all participants of
each group, normalized such that each participant contributes
with equal weight to the respective histograms. In the distribution
of saccade peak velocities (Figure 5A), a preference for horizontal
movements is evident in all groups, which is particularly pro-
nounced in PSP patients, reflecting their prominent reduction in
vertical peak velocity. Interestingly, this difference between groups
was less evident when analyzing all eye movements (Figure 5B).
We quantified the spread in each direction by standard deviation.
When considering all unclassified eye movements, there were no
significant differences among the groups [vertical: F(2, 28) = 1.74,
p = 0.19; horizontal: F(2, 28) = 1.86, p = 0.18]. When instead
considering saccades only (Figure 5A), a picture consistent with
the analysis above (section “Real-Life”) emerged: the standard
deviation of saccade peak velocities yielded highly significant dif-
ferences between the groups [vertical: F(2, 28) = 8.53, p = 0.001;
horizontal: F(2, 28) = 12.42, p < 0.001]. Significant differences
appeared between PSP and PD patients [vertical: t(19) = 3.38,
p = 0.003; horizontal: t(19) = 4.34, p < 0.001] as well as between
PSP patients and HCs [vertical: t(18) = 3.41, p = 0.003; horizon-
tal: t(18) = 3.75, p = 0.002]. Moreover, when testing analogous
measures to those that yielded significant differences and high
diagnostic power between patient groups for saccades (Figures 2
and 3), no significant effects were found for the full, unclas-
sified eye movement data. For example, the medians of all
velocities were not significantly different between the groups
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FIGURE 4 | (A) Saccade peak velocity plotted against saccade amplitude
(“main sequence”) for all individuals. Each data-point corresponds to
one saccade (note the cutoff to the bottom and left, given by the
thresholds on velocity and duration). Solid black line denotes best fitting
power functions (see section “Eye Movements”) in a least-squares
sense, dotted lines 5 and 95% confidence intervals. Fit parameters and
R2 are given in the panel headers. (B,C) Main-sequence fit
parameters of the functional relationship between peak velocity and
amplitude. (D,E) Main-sequence fit parameters for the functional
relationship between vertical component of peak velocity and amplitude.
(F,G) Main-sequence fit parameters for the functional relationship
between saccade duration and amplitude.
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FIGURE 5 | (A) Peak velocity histograms of cumulated saccades of all participants in each group (range: −900 to 900◦/s in the cardinal directions, bin size:
15◦ /s × 15◦ /s). (B) Velocity histograms of raw eye velocities of all cumulated data points of all participants in each group, same range, and bin size as in (A).
[F(2, 28) = 1.01, p = 0.38]. Notwithstanding some degree of arbi-
trariness in the definition of saccade thresholds, this indicates
that—at least under our recording conditions—the described
effects are best observed in fast movements.
HEAD MOVEMENTS
For 26 participants (9 PSP, 7 PD, and 10 HC) we successfully
obtained head data during the fixation protocol, for 27 (9 PSP,
9 PD, and 9 HC) during walking along the corridor without target
tracking, and for 29 (9 PSP, 10 PD, and 10 HC) while they tracked
the stationary target. In the remaining participants, head orienta-
tion was not recorded or recording was unsuccessful for technical
reasons. We chose to split walking the corridor into periods with
tracking and without tracking for head-in-world data considered
here, as we expected higher consistency with respect to the overall
head movements.
During the fixation protocol, all but one participant deviated
less than 2◦ from their average gaze orientation, 22/26 even less
than 1◦. Thus, head movements were small and rare, and the
median head velocity was below 2◦/s in all but one participant.
While this implies that participants complied with the instruction
to avoid head movements, it also means insufficient movements
to obtain robust velocity data.
During tracking, spread (quantified as standard deviations)
of head velocities was not significantly different between
groups [vertical: F(2, 26) = 0.49, p = 0.62, Figure 6A; horizontal:
F(2, 26) = 0.63, p = 0.54, Figure 6B]. During walking without
tracking, the vertical spread in velocity showed no dependence
on group [F(2, 24) = 0.51, p = 0.61, Figure 6C], either. In con-
trast, horizontal spread showed a significant group dependence
[F(2, 24) = 3.67, p = 0.04, Figure 6D], indicating that the absence
of an effect during tracking, where less participants contributed,
was not due to a lack of power. Importantly, this group depen-
dence resulted from a difference between PSP patients and
HCs [PSP-HC: t(16) = 3.41, p = 0.004], but not from a differ-
ence between patient groups [PSP-PD: t(16) = 0.01, p = 0.99] or
between PD patients and HCs [PD-HC: t(16) = 2.07, p = 0.055].
In sum, neither head orientation nor head velocity—to the extent
they could be analyzed with the present device—could offer any
parameters that might serve to discriminate PSP from PD.
DISCUSSION
In the present study we used a novel, wearable eye-tracking device
to assess gaze behavior in PD, PSP, and HCs. First, we demon-
strate that wearable eye-tracking distinguishes PSP from PD with
high sensitivity and specificity. Second, we show that these differ-
ences in gaze behavior are most prominent for saccades in a brief
fixation protocol and less pronounced in activities of daily living.
The observed differences between saccadic peak velocities in
the fixation protocol are highly consistent with earlier findings
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FIGURE 6 | (A,B) Spread of head velocity in (A) vertical and (B) horizontal
direction during walking while tracking a stationary target. (C,D) Spread of
head velocity in (C) vertical and (D) horizontal direction during walking
without specific instruction. Horizontal displacement of datapoints within
groups is for improved visibility only.
(Pinkhardt and Kassubek, 2011; Boxer et al., 2012). Similarly, the
lack of evidence for a difference in peak velocities between the
PD group and HCs are in line with previous data (Tanyeri et al.,
1989; Pinkhardt and Kassubek, 2011). As such, our data extend
earlier findings obtained using visually-guided saccades in stan-
dard laboratory setups to wearable eye-tracking, which allows
efficient assessment of these parameters in less restrained con-
ditions. Even though many sorts of eye movements are affected
by PSP, we focused on saccadic peak velocity and amplitude for
reasons of efficiency. Duration of saccades as conceivable alter-
native turned out to have less diagnostic power, despite some
difference in the average. Although amplitude, peak velocity, and
duration are not independent, but coupled through the “main
sequence,” the functional fit does not provide any additional
diagnostic power in real-life data, and requires more data than
available from the 20-s fixation protocol, such that amplitude
and peak velocity remain as the main diagnostic markers for
this rapid assessment. Still, if these two parameters should turn
out to be insufficient for differential diagnosis in a patients with
clinically uncertain diagnosis, other eye movements like vergence
and the linear vestibuloocular reflex can also be measured with
the EyeSeeCam.
The comparison between raw data and data filtered for sac-
cades allows three main conclusions. First, it stresses the specif-
ically prominent impairment of the saccade system for PSP
patients as compared to other eye movement systems (Chen
et al., 2010). Second, it underlines the importance of objec-
tive measurement devices to reliably detect potentially subtle eye
movement-related disease markers (Bartl et al., 2009). Finally,
the comparably mild differences in overall gaze orienting behav-
ior might point to a strategy how the specific deficits may be
compensated for and thus offers a promising path for carefully
quantifiable therapeutic intervention (Zampieri and Di Fabio,
2008).
The reduced differences in gaze behavior during activities of
daily living indicate that patients at least in part compensate
for their ocular motor deficits. Analysis of head movements,
however, suggests substantial inter-individual differences, indi-
cating that compensation strategies are largely idiosyncratic.
Predicting such compensation behaviors and relating them to
other parameters, such as disease progression, will be an inter-
esting issue for further research in larger, heterogeneous PSP
cohorts. In a longitudinal study, the precise quantification of
compensatory behavior might then also aid the efficient mon-
itoring of treatment success. For differential diagnosis, the free
exploration paradigm is clearly less valuable, demonstrating the
importance of a flexible, but at the same time standardized
fixation protocol for clinical use. Nonetheless, the free explo-
ration data may yield important information on compensation
mechanisms and the consequences of the disease on every-
day life.
In contrast to eye movements, the parameters considered for
head movements did not allow a significant dissociation between
patient groups under any of the tested tasks. This could be due
to the low spatial and temporal resolution of the head movement
measurements as compared to eye movement measurements. It
is conceivable that with an improved measurement device for
head movements, with different instructions or tasks, or when
effects on eye-head coordination are measured with sufficient
spatial and temporal accuracy and precision, head movements
might eventually become useful and could augment a PSP/PD
discrimination system. However, with the present technology and
based on the tasks used in the present study, eye velocity and
amplitude during the fixation protocol present a most promis-
ing candidate for dissociating PSP from PD also in subclinical
populations.
This study is to be regarded as a first step toward establishing
a new method as a diagnostic tool. Prospective studies measur-
ing eye movements of still unclassified patients are needed to
prove that subclinical oculomotor disturbances can be detected
prior to the establishment of the clinical diagnosis. Also, square
wave jerks which are characteristic of PSP patients could only
be detected in one PSP patient, even by careful visual inspec-
tion of all eye movement traces. While beyond the scope of
the present study, the question as to whether their absence from
the measured data is a technical limitation or a true effect of the
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population and condition at hand remains an important issue for
future research.
Importantly for a possible application in diagnosis and treat-
ment monitoring, the usage of the wearable eye-tracking device
is efficient, requiring less than 20-s for the fixation protocol
and virtually no device-specific training. While wearable eye-
tracking has recently been suggested as tool in a variety of ocular
motor and vestibular conditions (Hayhoe and Ballard, 2005;
Schumann et al., 2008), the present study demonstrates that wear-
able eye-tracking also lends itself for efficient clinical use in the
context of more complex syndromes, such as typical and atypical
Parkinsonism. Whether or not wearable eye-tracking will allow
diagnosis beyond the current gold standard obviously can only be
established in a long-term longitudinal prospective study, which
will apply the criteria found herein already early during disease,
when current clinical criteria are not yet clear cut.
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Movie 1 | Example movies of two participants, PD07 and PSP09, showing
a part of the real-life measurement. Histograms picture eye velocity (left
panel, range: −500 to 500◦ /s in the cardinal directions, bin size for this movie:
5◦/s × 5◦/s) and head velocity (right panel, range: −60 to 60◦/s in the cardinal
directions, bin size: 3◦/s × 3◦/s).
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